Results 231 to 240 of about 38,575 (293)

A Temporal Association between Regression of Pachydrusen and Use of Proprotein Convertase Subtilisin Kexin 9 Inhibitor: A Case Report. [PDF]

Case Rep Ophthalmol
Chantarasorn Y, Funilkul K.
europepmc   +1 more source

Effects of Serum Estradiol on Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Lipid Profiles in Women Undergoing In Vitro Fertilization. [PDF]

J Cardiovasc Dev Dis
Papanikolaou A, Anastasiou G, Barkas F, Tellis C, Zikopoulos K, Liberopoulos E.   +5 more
europepmc   +1 more source

The Application of Peptide Nucleic Acids (PNA) in the Inhibition of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Gene Expression in a Cell-Free Transcription/Translation System. [PDF]

Int J Mol Sci
Polak A, Machnik G, Bułdak Ł, Ruczyński J, Prochera K, Bujak O, Mucha P, Rekowski P, Okopień B.   +8 more
europepmc   +1 more source

Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation. [PDF]

AIDS
Gandhi MM, Nguyen KL, Lake JE, Liao D, Khodabakhshian A, Guerrero M, Shufelt CL, Bairey Merz CN, Jordan WC, Daar ES, Bhattacharya D, Chew KW.   +11 more
europepmc   +1 more source

Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes. [PDF]

J Extracell Vesicles
Ilahibaks NF, Kluiver TA, de Jong OG, de Jager SCA, Schiffelers RM, Vader P, Peng WC, Lei Z, Sluijter JPG.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The biology and therapeutic targeting of the proprotein convertases

Nature Reviews Drug Discovery, 2012
The mammalian proprotein convertases constitute a family of nine secretory serine proteases that are related to bacterial subtilisin and yeast kexin. Seven of these (proprotein convertase 1 (PC1), PC2, furin, PC4, PC5, paired basic amino acid cleaving enzyme 4 (PACE4) and PC7) activate cellular and pathogenic precursor proteins by cleavage at single or
Nabil G Seidah, Annik Prat
exaly   +4 more sources

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition

Biofactors, 2020
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has a crucial role in lipid metabolism, particularly due to its function in low‐density lipoprotein receptor degradation.
A. Cesaro, V. Bianconi, F. Gragnano, E. Moscarella, F. Fimiani, E. Monda, O. Scudiero, G. Limongelli, M. Pirro, P. Calabrò   +9 more
semanticscholar   +1 more source

Proprotein convertases as therapeutic targets

Expert Opinion on Therapeutic Targets, 2008
Limited endoproteolysis of precursor proteins is a common mechanism of production of functional proteins and peptides. In the secretory pathway of eukaryotic cells, this endoproteolysis is principally mediated by a family of calcium-dependent serine proteases, generically known as proprotein convertases.
Michel Chrétien, Majambu Mbikay, Nabil G. Seidah, Ajoy Basak   +3 more
openaire   +3 more sources

Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: a systematic review and meta-analysis.

Journal of Cardiovascular Pharmacology, 2020
Lipoprotein(a) (Lp(a)) is a cardiovascular factor, for which there is no approved specific lowering treatment. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to have lowering effects on Lp(a).
I. Farmakis, I. Doundoulakis, A. Pagiantza, S. Zafeiropoulos, C. Antza, H. Karvounis, G. Giannakoulas   +6 more
semanticscholar   +1 more source